Complementary and Alternative Medical Lab Testing Part 11: Men

By Ronald Steriti

Complementary and Alternative Medical Lab Testing (CAM Labs) contains summaries of the published research on lab tests, primarily from PubMed trials on humans. Each chapter (disease) begins with a brief summary of conventional lab tests, followed by additional lab tests, including diabetes, insulin resistance, metabolic syndrome, inflammation, etc. There are sections on endocrine hormones (thyroid, adrenal, sex steroids) and environmental medicine (toxic heavy metals). The nutritional assessments section includes minerals, vitamins and amino acids.

CAM Labs 11 – Men

1. Benign Prostatic Hyperplasia
2. Erectile Dysfunction
3. Gynecomastia, Male
4. Infertility, Male
5. Prostatitis
6. Well Man

• Language: English
• Publisher: Ronald Steriti
• Release date: Jun 4, 2016
• ISBN: 9781311900913

Ronald Steriti

Dr. Ronald Steriti is a graduate of Southwest College of Naturopathic Medicine and currently is researcher for Jonathan V. Wright at the Tahoma Clinic.

Book preview

Complementary and Alternative

Medical Lab Testing

Part 11: Men

By Ronald Steriti, ND, PhD

©

Complementary and Alternative Medical Lab Testing Clinician’s Guide Part 11: Men

By Ronald Steriti, ND, PhD

Copyright © 2016

All rights reserved. No part of this book may be reproduced in any form or by any means, including photocopying, including in a web site, or stored in a retrieval system, or transmitted in any form by any means, without expressed, written permission of the copyright owner.

The contents of this document are the sole property of the author.

Disclaimer

This book has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease.

The information contained in this book is for educational purposes only, and should not be construed as medical advice or instruction. No action should be taken based solely on the contents of this book. Readers should consult appropriate health officials.

While extensive efforts have been made to ensure the accuracy of the information contained, the possibility of errors, omissions, and misinterpretations cannot be ruled out. The reader is advised to consult the original references for verification and clarification.

Foreward

This book is a summary the published research on lab tests, primarily from PubMed. The studies are limited to those with trials on humans. As such, some labs may be excluded due to the lack of published research. That is simply a reflection of the current state of research - much more work is needed!

Although this book may be useful for differential diagnosis, lab tests are can also be used to identify inderlying causes and associated conditions.

The sections on conventional lab tests are purposefully brief. These tests are typically used to confirm a diagnosis. There are other more comprehensive sources of information on conventional medical lab testing.

Table of Contents

1. Benign Prostatic Hyperplasia

2. Erectile Dysfunction

3. Gynecomastia, Male

4. Infertility, Male

5. Prostatitis

6. Well Man

Chapter 1. Benign Prostatic Hyperplasia

Conventional Lab Tests

Prostate specific antigen (PSA)

Electrolytes, BUN and Creatinine

Additional Lab Tests

Fasting Glucose, Hemoglobin A1C

One hundred and seventeen geriatric patients with BPH were retrospectively studied between 2008 and 2009. Patients were divided into two groups: BPH and BPH with DM group. The values of prostate volume (PV) (P = 0.005), PSA (P = 0.013), and IPSS (P = 0.01) in the BPH patients with DM group were significantly higher than in the BPH group. The values of PV (P = 0.002) and PSA (P = 0.006) in the BPH patients with elevated FBG were significantly higher than in the BPH patients with normal FBG. BPH patients with elevated HbA1c had significantly higher PV than BPH patients with normal HbA1c (P = 0.046). BPH with hyperinsulinemia group showed significantly higher PV (P = 0.017) and longer duration of LUTS (P = 0.031) than BPH patients with normal FINS. Similarly, BPH patients with IR had higher PV (P = 0.004) and longer duration of LUTS (P = 0.036) than BPH patients without IR. The logistic regression analysis showed that FBG and FINS were the risk factors for BPH. This study demonstrates that PV is closely correlated with diabetes and diabetes has a direct effect on the occurrence and development of BPH. (Qu et al., 2013)

Insulin Resistance, Metabolic Syndrome

A total of 1224 male police officers aged 50-59 years who had participated in a health examination were included. The subjects were classified into 4 groups according to the number of exhibited MetS components (0, 1-2, 3, and 4-5). We used the Mantel-Haenszel extension test and logistic regression analyses. MetS was diagnosed in 29.0% of the patients. The BPH ratio (IPSS >7, TPV >/=30 mL, and/or Qmax <15 mL/sec), TPV >/=30 mL, and PVR >/=50 mL significantly increased with an increasing number of metabolic abnormalities. The odds ratio (OR) in relation to a TPV >/=30 mL and a PVR >/=50 mL significantly rose as the number of positive MetS components increased after adjusting for age and testosterone. Additionally, the ORs (adjusting for age and testosterone) in relation to BPH also increased as the number of positive MetS components increased, with a suggestive threshold effect associated with 4-5 positive components (BPH: IPSS >7 + TPV >/=30 mL; 4 and 5 components, 3.496, 1.805-6.769, P = .001; BPH: IPSS >7 + TPV >/=30 mL + Qmax <15 mL/sec; 4 and 5 components, 5.458, 1.777-16.764, P = .002). According to these results, the cases of LUTS/BPH were positively associated with the number of MetS components. (Park et al., 2013)

A total of 778 male police officers in their 50s with moderate to severe lower urinary tract symptoms (International Prostate Symptom Score > 7) were included in the present study. We defined the predictors of the risk of clinical progression of BPH as the total prostate volume >/=31 cm(3), prostate-specific antigen level >/=1.6 ng/mL, maximal flow rate <10.6 mL/s, and postvoid residual urine volume of >/=39 mL. The MetS was defined using the National Cholesterol Education Program-Adult Treatment Panel III guidelines. We used the Mantel-Haenszel extension test and logistic regression analyses to statistically examine their relationship. The percentage of participants with >/=1 predictor for the progression of BPH, the percentage of participants with a total prostate volume of >/=31 cm(3), and the percentage of participants with a postvoid residual urine volume of >/=39 mL increased significantly with the increase in the number of components of the MetS (P = .003, P = .001, and P = .007, respectively). After adjusting for age and serum testosterone levels, the MetS was shown to be significantly associated with the presence >/=1 predictor for the progression of BPH (odds ratio 1.423, 95% confidence interval 1.020-1.986). The data have shown that the MetS is associated with the predictors of the risk of clinical progression of BPH in men in their 50s with moderate to severe lower urinary tract symptoms. (Kwon et al., 2013)

Subjects aged 45 years or older who voluntarily underwent a medical checkup were enrolled. During January through December of 2010, 708 subjects with a mean age of 55.6 +/- 9.72 years were enrolled into the study. Compared to the nonmetabolic syndrome group, the metabolic syndrome group had lower total international prostatic symptoms score (7.89 +/- 6.63 vs 6.85 +/- 6.52, P = .05) and lower severity of weak urinary stream (1.24 +/- 1.60 vs 0.95 +/- 1.50, P = .021). In the higher prostate volume group (prostate volume >/= 30 mL), total international prostatic symptoms score, storage score, and urinary frequency, urgency and incomplete emptying were lower in men vs those without metabolic syndrome (all P < .05). The negative association between voiding score, severity of lower urinary tract symptoms, and metabolic syndrome became particularly pronounced as the number of metabolic syndrome factors increased (P for trend < .01). This study confirmed that metabolic syndrome